Skip to main content
Smart Investors Daily
Biohaven Ltd. logo

NASDAQ · BHVN

Biohaven Ltd.

Healthcare · Biotechnology

$13.82

Down-$0.02 (-0.14%)

Updated Nov 17, 2026, 12:13 AM

SID Score

5.5/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
1.21B
P/E ratio
-1.55
Dividend yield
0.00%
52-week range
$8.03 – $18.24
Volume
1.26M
Avg. volume
3.75M

Price performance · BHVN

BHVN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 13, 2026

BHVN closed at $13.82 after 20 trading sessions, up 21.76% for the selected period.

Last close
$13.82
Period change
+21.76%
Period low
$11.35
Period high
$16.49
Daily close
View OHLC price history
BHVN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 13, 2026$14.29$14.29$13.37$13.821.26M
Nov 12, 2026$15.00$15.1777$14.04$14.071.63M
Nov 11, 2026$15.09$15.41$14.98$15.191.6M
Nov 10, 2026$15.05$15.43$14.355$15.111.78M
Nov 9, 2026$14.79$15.50$14.26$15.233.63M
Nov 6, 2026$14.23$14.495$13.76$14.482.92M
Nov 5, 2026$15.11$15.11$13.84$13.903.47M
Nov 4, 2026$15.97$16.15$15.12$15.241.68M
Nov 3, 2026$15.46$16.09$15.25$15.612.02M
Nov 2, 2026$15.98$16.105$15.08$15.162.59M
Oct 30, 2026$15.46$16.33$15.12$15.423.16M
Oct 29, 2026$15.46$16.49$15.46$16.492.45M
Oct 28, 2026$15.11$15.87$14.955$15.523.15M
Oct 27, 2026$14.44$15.30$14.13$15.292.43M
Oct 26, 2026$13.94$14.6973$13.695$14.452.68M
Oct 23, 2026$15.215$15.37$13.83$13.884.69M
Oct 22, 2026$16.10$16.54$14.45$14.6930.51M
Oct 21, 2026$11.90$12.1647$11.625$11.751.44M
Oct 20, 2026$11.35$11.845$11.07$11.811.53M
Oct 19, 2026$11.01$11.52$10.865$11.351.69M

Latest BHVN news

The latest Smart Investors Daily articles mentioning BHVN.

BHVN research

Overview

Company profile and research snapshot.

Company profile

Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$22.50
Implied upside
—
Analysts
—
BHVN recent ratings
DateFirmRatingTarget
Nov 3, 2026Morgan StanleyOverweight—
Oct 30, 2026Canaccord GenuityBuy—
Oct 23, 2026RBC CapitalSector Perform—
Sep 10, 2026HC Wainwright & Co.Neutral—
Sep 8, 2026RBC CapitalSector Perform—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 5, 2026

Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting

Biohaven Ltd. (NYSE: BHVN) (Biohaven) today announced continued progress across its Graves' disease program, including active enrollment in the pivotal Phase 3 trial of BHV-1300 and three scientific presentations at the 2026 American Thyroid Association (ATA) Annual Meeting in Philadelphia, Pennsylvania. Together they describe a program that extends from the molecule in pivotal testing, to the patient experience that defines the need for it, to the underlying autoantibody biology that Biohaven c

Benzinga · Nov 5, 2026

Biohaven Announces Progress Across Its Graves' Disease Program, Including Active Enrollment In Pivotal Phase 3 Trial Of BHV-1300 And Three Scientific Presentations At The American Thyroid Association Meeting; Phase 3 Trial Of BHV-1300 In Graves' Disease Is Enrolling At 55+ Active Sites In U.S. And Canada, With More Opening In UK, Japan, Australia And EU

Biohaven presents three posters at ATA, highlighting the patient experience, autoimmune biology of disease, and MoDE and TRAP platform, reflecting a research program built around a condition that remains strikingly

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.